Loading patent…
AssigneeEmory University
InventorsEdmund Waller, Anna Morris, Christopher Petersen, Jian-Ming Li, Reema Panjwani, Jingxia Li
Estimating the term…
This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.
An in vitro cell culture composition comprising purified T cells and a VIP receptor antagonist and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.
An in vitro cell culture composition comprising purified T cells and a VIP degrading enzyme and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.
An in vitro cell culture composition comprising purified T cells and a phosphatidylinositol-3-kinase inhibitor and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.
A method of treating cancer or a chronic infection comprising:
A method of treating cancer comprising administering an effective amount of a bi-specific antibody in combination with a VIP receptor antagonist or phosphatidylinositol-3-kinase inhibitor to a subject in need thereof, wherein the bi-specific antibody comprises a cancer targeting binding sequence and a CD3 binding sequence.
Dependencies are inferred from the claim text.